Tarek Sahmoud, MD

home / authors / tarek-sahmoud-md

Articles

20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer

20 TIP ELONA: An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor– Positive, Progesterone Receptor– Positive, HER2-Negative Advanced or Metastatic Breast Cancer

Erika P. Hamilton, MD;Lajos Pusztai, MD, DPhil;Hatem Soliman, MD;Sara A. Hurvitz, MD;Krzysztof J. Grzegorzewski;Nassir Habboubi;Priya Marreddy;Tarek Sahmoud, MD;Nuhad Ibrahim, MD
April 28th 2023
21 TIP ELECTRA: An Open- Label, Multicenter, Phase 1b/2 Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2– Negative (HER2–) Breast Cancer

21 TIP ELECTRA: An Open- Label, Multicenter, Phase 1b/2 Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD), in Combination With Abemaciclib in Patients With Brain Metastasis From Estrogen Receptor–Positive (ER+), HER2– Negative (HER2–) Breast Cancer

Erika P. Hamilton, MD;Sung-Bae Kim;Neelima Vidula, MD;Simona Scartoni;Tarek Sahmoud, MD;Bartomeu Piza Vallespir;Kathy Puyana Theall;Nassir Habboubi;Nuhad Ibrahim, MD
April 27th 2023
55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)

55 TIP ELEVATE: A Phase 1b/2, Open-Label, Umbrella Study Evaluating Elacestrant in Various Combinations in Women and Men With Metastatic Breast Cancer (mBC)

Hope S. Rugo, MD;Aditya Bardia, MD, MPH;Javier Cortes;Giuseppe Curigliano;Erika P. Hamilton, MD;Sara A. Hurvitz, MD;Sibylle Loibl;Simona Scartoni;Tarek Sahmoud, MD;Krzysztof J. Grzegorzewski;Nassir Habboubi;Joyce A. O’Shaughnessy
April 27th 2023
Site Logo

Cisplatin/Paclitaxel vs Cisplatin/Teniposide for Advanced Non-Small-Cell Lung Cancer

Giuseppe Giaccone, MD, PhD;Pieter E. Postmus, MD, PhD;Ted A. W. Splinter, MD;Maria Diaz-puente, MD;Nico Van Zandwijk, MD, PhD;Giorgio V. Scagliotti, MD, PhD;Andrea Ardizzoni, MD;Jan Van Meerbeeck, MD;Channa Debruyne, MD;Tarek Sahmoud, MD
April 1st 1997

A total of 332 patients with advanced non-small-cell lung cancer were randomized by the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative

Latest Updated Articles

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
Initial Workup for a Newly Diagnosed Pancreatic Cancer Patient
Published: November 7th 2024 | Updated: November 21st 2024
Initial Workup for a Newly Diagnosed Pancreatic Cancer Patient
Treatment Considerations for Disease Progression
Published: November 7th 2024 | Updated: November 21st 2024
Treatment Considerations for Disease Progression
Treatment Paradigm for Metastatic Pancreatic Cancer
Published: November 7th 2024 | Updated: November 21st 2024
Treatment Paradigm for Metastatic Pancreatic Cancer